Company news: Merck, Millennium, Novo Nordisk and Genentech

Share this article:

Merck can update its Vytorin label with data suggesting a cardiovascular benefit in patients with kidney disease, the drugmaker said, but may not claim a new indication. That was the FDA's decision, despite a unanimous vote by an advisory panel in favor of the pre-dialysis outcome. The vote had followed release of data from the SHARP trial, in which Vytorin (ezetimibe/simvastatin) reduced major vascular events in patients with moderate-to-severe chronic kidney disease (CKD). The FDA permitted no such label update for Vytorin's LDL-lowering cousin, Zetia (ezetimibe).

Biotechs made a showing in Fortune Magazine's list of 100 Best Companies to Work For, starting with Millennium: The Takeda Oncology Company, which placed at 35 and was followed closely by Novo Nordisk at 43. Genentech was No. 68.

Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters